X

2014 Breast Cancer Awareness Month

I will donate:

National Breast Cancer Coalition

For Immediate Release:

NBCC and BioMarin Pharmaceutical Inc. Collaborate on BMN 673

NBCC advocates to work side-by-side with company and clinical investigators to evaluate the safety and efficacy of BMN 673 in the metastatic setting

Washington, D.C., July 29, 2013—The National Breast Cancer Coalition (NBCC) and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) have announced a collaboration to develop BioMarin’s PARP inhibitor for the treatment of hereditary breast cancer with BRCA mutations. NBCC will have input and representation in study design, implementation and execution. In addition, NBCC will support trial enrollment initiatives in the United States and around the world.  BioMarin is planning to initiate a Phase 3 trial for BMN 673 in deleterious gBRCA mutation metastatic breast cancer in the fall.

"NBCC is committed to ending breast cancer in large part by participating in and contributing to the scientific process," said Fran Visco, President of the National Breast Cancer Coalition. "We have built a network of trained, committed advocates dedicated to collaborating with scientists to advance meaningful research. Our involvement with clinical trials is an important component of that work. We are pleased to collaborate with BioMarin to develop BMN 673 as a potential first best in class PARP inhibitor for patients with hereditary forms of cancer, namely BRCA mutations. This project offers the hope of improving the length and quality of life for patients already diagnosed."

Since its inception, NBCC has been educating and empowering women and men as advocates, increasing the involvement and influence of those living with breast cancer and other breast cancer activists wherever and whenever breast cancer decisions are made. This collaboration with BioMarin is part of NBCC’s long-standing Clinical Trials Initiative to support clinical trials involving innovative approaches to prevention and treatment; enhance access to quality, meaningful clinical trials; and bring the perspective of trained advocates to all aspects of trial development, implementation and oversight. NBCC advocate involvement has been key in several trials including the pivotal trial of trastuzumab and the ongoing TAILORx trial.

Advocates receive training through NBCC’s intensive science training program, Project LEAD®. NBCC partnership decisions on clinical trials follow rigorous criteria including significance of the research question, rigor of study design and ethical conduct of the trial among others. The BioMarin clinical trial proposed for BMN 673 meets those criteria.

"We look forward to conducting a world-class study, in collaboration with the finest clinical investigators in the world to evaluate the safety and efficacy of BMN 673 in the metastatic setting. Our advocates are poised to change the world through our actions. Ultimately, we hope to prevent women from getting breast cancer and prevent it from spreading outside the breast," Visco added.

"BioMarin wants to make big differences in the lives of patients. We are honored to include a seat at the table for our colleagues from NBCC. Our efforts are best served by hearing their voice from the beginning and taking action together," said Hank Fuchs, Chief Medical Officer of BioMarin.

About the National Breast Cancer Coalition (NBCC)
The National Breast Cancer Coalition (NBCC) is dedicated to knowing how to end breast cancer by January 1, 2020 through the power of grassroots action and advocacy. NBCC supports increasing funding for innovative breast cancer research; monitors how those funds are spent; expands access to quality health care for all; and ensures that trained advocates influence all decision making in breast cancer. Join NBCC, learn more and take action. Visit BreastCancerDeadline2020.org.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.

###

Press release Footer